Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

Success in the ARIEL3 trial for its ovarian cancer agent and a collaboration with Bristol-Myers Squibb has put Clovis in a healthy position, CEO Patrick Mahaffy tells Scrip.

For biopharma, launching first products, and especially sudden profitability, doesn't necessarily predict which companies will succeed. Instead, an examination of stock market success shows the need to bring a succession of drugs, or at least additional indications, into clinical trials-mostly through aggressive deal-making.

Unlike many biotechs, Vertex has consistently cast itself as a product-focused company. To get there, Vertex built a remarkably productive discovery engine that has generated an impressive development pipeline. But to date, the company has produced only one commercial product, an HIV therapy marketed by GSK. That relatively slow path to commercialization is in large part attributable to the company's reliance on its internal R&D to produce drugs. By eschewing the in-licensing path that other biotechs have taken to jumpstart their commercial development, and partnering away commercial rights to a number of its later-stage compounds, the company has left some doubting its commitment to marketing its own drugs. But Vertex is now laying the foundation for creating a full-fledged commercial capability. And if the company can stay on track as it tackles the challenges of integrating a commercial operation into its organization, it may prove the skeptics wrong and accomplish something that perhaps no other biotech has: create a fully integrated pharmaceutical firm on the back of its own R&D.